<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747133</url>
  </required_header>
  <id_info>
    <org_study_id>18-5481</org_study_id>
    <nct_id>NCT03747133</nct_id>
  </id_info>
  <brief_title>SABR for Renal Tumors</brief_title>
  <official_title>Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for
      this type of cancer is surgery. Considering the most common patients are an average age of 65
      and some are not suitable candiates for surgery, there is great interest in non-surgical
      alternatives for kidney cancer treatments. This study will investigate the use of
      Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive
      alternative, which involves delivery of high doses of radiation to the target, while
      minimizing the risk of injury to the surrounding organs. Patients will be seen before and end
      of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow
      ups, patients will be asked to complete a quality of life questionnaire and will have
      standard of care imaging.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the radiation induced renal impairments in patients receiving SABR.</measure>
    <time_frame>2 years</time_frame>
    <description>The prevalence of nephron toxicity in patients treated with SABR, measured by the change in Glomerular Filtration Rate (GFR) every 4 months over 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Kidney Disease Stage Progression</measure>
    <time_frame>2 years</time_frame>
    <description>Chronic kidney disease stage progression after SABR, assessed by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Local recurrence rate</measure>
    <time_frame>2 years</time_frame>
    <description>2 year local recurrence rate of kidney tumors treated with SABR, measured by assessing the change of irradiated kidney function on functional imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>The change in quality of life of patients treated with SABR, assessed through the use of NCCN FKSI-19 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence of acute (≤3 months) and late complication of interest (GI or GU complications, high blood pressure and adrenal insufficiency) as assessed by CTCAE version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Tumor</condition>
  <arm_group>
    <arm_group_label>Stereotactic Ablative Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with Kidney mass (either primary or metastasis) amenable to SABR</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy</intervention_name>
    <description>Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.</description>
    <arm_group_label>Stereotactic Ablative Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm

          -  Histological or radiological diagnosis of renal tumor

          -  Inoperable: High risk for surgery or declined surgery

          -  ECOG performance status of 0-3

        Exclusion Criteria:

          -  ≥5 active metastases

          -  Sysstemic therapy (except endocrine therapy) wthin 6 days prior to SABR

          -  Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the
             involved kidney

          -  Patients with end stage renal failure &gt; 4(KDOQI guidelines)

          -  Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary
             Papillary RCC or Tuber Sclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joelle Helou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network--Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joelle Helou, MD</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>4866</phone_ext>
    <email>joelle.helou@rmp.uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle Helou, MD</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4866</phone_ext>
      <email>joelle.helou@rmp.uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Joelle Helou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Bayley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <keyword>SABR</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>RCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

